Stockpolly
Search
BOLD · NASDAQ · Biotechnology

Boundless Bio (BOLD)

Wind-down-stage ecDNA oncology developer pursuing a merger with Serapha Bio.

$2.90
At close+0.00 (+0.17%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
151417191918171715141424
Research & development121013141413121210101014
3345555544510
General & administrative3345555544510
Other expenses000000000−100
Operating income−15−14−17−19−19−18−17−17−15−14−14−24
221222211111
Interest income221222211111
Other non-operating income0−2−1−2−2−2−2−1−1−1−1−1
Income before tax−13−12−15−17−17−16−16−16−14−13−14−24
Net income from continuing operations−13−12−15−17−17−16−16−16−14−13−14−24
Net income−13−12−15−17−17−16−16−16−14−13−14−24
EPS, basic−$0.59−$0.55−$0.69−$0.77−$0.74−$0.84−$0.71−$0.70−$0.62−$0.58−$0.60−$1.06
EPS, diluted−$0.59−$0.55−$0.69−$0.77−$0.74−$0.84−$0.71−$0.70−$0.62−$0.58−$0.60−$1.06
Weighted average shares, basic222222222217222222222222
Weighted average shares, diluted222222222217222222222222
EBITDA−15−12−15−17−16−16−15−15−14−13−13−19
Depreciation & amortization000000000004
EBIT−15−12−15−17−17−16−16−16−14−13−14−24